Physician profile
Karissa Wright Boyd
NPI 1225135981
$7,811.36
in general payments reported to CMS, 2019-2025
62 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $145 · 2021: $504 · 2022: $1,250 · 2023: $1,714 · 2024: $1,782 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,326 · Education: $29.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,326.40 |
| Education | $29.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $685.68 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $653.98 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $569.12 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $535.82 | 2019-2025 | |
| Gilead Sciences, INC. | $400.75 | 2019-2025 | Trodelvy |
| Daiichi Sankyo INC. | $353.61 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $353.50 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $352.41 | 2019-2025 | Darzalex, Erleada, Imbruvica |
| Amgen INC. | $281.17 | 2019-2022 | |
| Lilly USA, LLC | $229.86 | 2019-2025 | Jaypirca, Verzenio |
| Incyte Corporation | $212.79 | 2021-2025 | Monjuvi, Jakafi |
| Abbvie INC. | $203.66 | 2022-2025 | Venclexta |
| Exelixis INC. | $174.60 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $173.45 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Glaxosmithkline, LLC. | $166.00 | 2021-2025 | Jemperli, Zejula, Ojjaara |
Show all 61 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karissa Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.